SageView Advisory Group LLC Invests $333,000 in Kenvue Inc. (NYSE:KVUE)

SageView Advisory Group LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 15,581 shares of the company’s stock, valued at approximately $333,000.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Geode Capital Management LLC grew its holdings in Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock valued at $980,989,000 after buying an additional 1,391,854 shares during the last quarter. Franklin Resources Inc. increased its position in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after buying an additional 16,269,721 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kenvue by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock worth $533,169,000 after buying an additional 561,570 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $22.96 on Wednesday. The business has a 50 day simple moving average of $22.75 and a 200 day simple moving average of $22.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $43.87 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.57%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. Barclays cut their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, UBS Group lowered their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.